RCT Forms Company to Develop Pharmaceuticals from Synthetic DHEA
Tucson, AZ – Dec 11, 1995
Research Corporation Technologies (RCT) has formed Aeson Therapeutics Inc. to further ongoing development of therapeutic agents from a synthetic version of dehydroepiandrosterone, or DHEA.
The patented DHEA analog, called fluasterone, was developed by Dr. Arthur G. Schwartz and others at the Temple University Fels Institute for Cancer Research and Molecular Biology. RCT manages the technology for Temple University.
The human adrenal gland manufactures DHEA in large amounts, yet the biological role of the steroid in humans is only partially understood. Over the past several years, Schwartz’ laboratory and others have shown that DHEA is an important mammalian hormone. In animal tests, DHEA inhibits development of breast, lung, colon, liver and skin tumors and also produces antiobesity, antidiabetic, antiatherosclerotic and cholesterol-lowering effects.
Preliminary clinical data show that DHEA has antidiabetic and cholesterol-lowering effects in humans. Yet the male hormonal side effects of the steroid limit the use of DHEA in humans, particularly women. Fluasterone lacks these side effects and shows greater efficacy in animals.
Aeson’s development plan focuses on testing the potential efficacy of fluasterone in preventing breast cancer, and as a treatment for lupus erythematosus and Type II diabetes. The company has funding to carry out its initial clinical development plan. This plan is designed to show fluasterone’s non-androgenicity in humans and to establish its efficacy in preventing breast cancer and other indications. Aeson is currently negotiating a clinical trials agreement with the Cancer Chemoprevention Program of the National Cancer Institute to test fluasterone as a breast cancer preventive.
Aeson’s chairman, Jeffrey E. Jacob, said that following the company’s initial clinical trials, “Aeson hopes to continue fluasterone development in partnership with a major pharmaceutical company.”
For additional information, contact:
Jeffrey E. Jacob
Aeson Therapeutics Inc.
Telephone (520) 748-4417
Fax (520) 748-0025